Welcome to our dedicated page for Sionna Therapeutics SEC filings (Ticker: SION), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sionna Therapeutics, Inc. (Nasdaq: SION) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Sionna describes itself as a clinical-stage biopharmaceutical company focused on developing CFTR-targeted therapies for cystic fibrosis, and its filings offer detail on this business and its financial position.
Among the key documents available are current reports on Form 8-K, where Sionna furnishes press releases announcing quarterly financial results and business highlights. For example, the company has used Form 8-K to present information on research and development expenses, general and administrative expenses, net loss, cash and cash equivalents, and progress across its clinical pipeline of NBD1 stabilizers and complementary CFTR modulators.
In addition to 8-Ks, investors typically look to annual reports on Form 10-K and quarterly reports on Form 10-Q for broader discussions of risk factors, research and development activities, and the company’s focus on cystic fibrosis therapies. These filings can also describe Sionna’s status as an emerging growth company, its operating segment dedicated to CF drug development, and other structural aspects of the business.
Stock Titan enhances access to SION filings by pairing real-time updates from the EDGAR system with AI-powered summaries that explain the significance of each document in clear language. Users can quickly identify items related to clinical trial progress, financial condition, and other material events, and can review insider and management-related disclosures where applicable. This page serves as a central location for reviewing Sionna’s regulatory history and understanding how its CF-focused strategy is reflected in formal SEC documents.
OrbiMed Private Investments VIII, LP reported proposed sales of Common Stock in an amended Form 144/A, listing multiple share dispositions between 04/14/2026 and 05/27/2026. The amendment itemizes individual transactions, including sales of 235,863 shares for $10,528,924.32 on 04/15/2026 and 184,639 shares for $8,534,014.58 on 05/11/2026.
OrbiMed Private Investments VIII, LP, an entity associated with Sionna Therapeutics director Peter A. Thompson, sold 101 shares of Sionna Therapeutics common stock at $44.49 per share in an open-market transaction on May 27, 2026.
The sale was executed pursuant to a Rule 10b5-1 trading plan. After this transaction, entities associated with OrbiMed continued to hold 2,671,721 shares indirectly, indicating that only a very small portion of the overall indirect position was sold.
OrbiMed-affiliated entities reported a small open-market sale of Sionna Therapeutics stock under a pre-set trading plan. An entity associated with OrbiMed sold 101 shares of Sionna Therapeutics, Inc. common stock at $44.49 per share on May 27, 2026, in an open-market transaction pursuant to a Rule 10b5-1 plan.
After this sale, OrbiMed-related holdings reported in this filing totaled 2,671,721 shares of common stock, held indirectly through OrbiMed Private Investments VIII, LP. The OrbiMed reporting entities and certain principals disclaim beneficial ownership beyond any pecuniary interest.
SION submitted a Form 144 reporting proposed and completed sales of Common Stock by a selling holder. The filing lists multiple dispositions by OrbiMed Private Investments VIII, LP across 04/14/2026–05/27/2026, including lots of 235,863 shares on 04/15/2026 and 184,639 shares on 05/11/2026. The filing names the issuer, shows the securities class as Common Stock, and reports proceeds for each sale in dollars.
Viking Global Investors LP amended its Schedule 13G/A to remove David C. Ott as a reporting person effective March 31, 2026. The filing restates beneficial ownership by related Viking entities and individuals: 3,195,181 shares (representing 7.1% of the class) held through affiliated funds and GPs.
The amendment details that 2,039,801 shares are directly owned by Viking Global Opportunities Sub‑entities and 1,155,380 shares by Viking Global Opportunities Drawdown entities, with shared voting and dispositive power across the reported affiliates and two executive committee members.
Sionna Therapeutics Inc ownership update: Qatar Investment Authority, through wholly owned Q Healthcare Holding LLC, reports beneficial ownership of 2,020,258 shares of Common Stock, representing 4.5% of the class. The Schedule 13G/A amendment identifies sole voting and dispositive power over these shares.
Sionna Therapeutics reports first-quarter 2026 results showing a net loss of $26.8 million, wider than $16.5 million a year earlier, as it invests heavily in cystic fibrosis drug development. Research and development expenses rose to $19.0 million and general and administrative costs to $10.6 million, both driven mainly by higher headcount and stock-based compensation.
The company ended March 31, 2026 with $289.9 million in cash, cash equivalents and marketable securities and expects this to fund operations into 2028. Sionna is running a Phase 2a trial of NBD1 stabilizer SION-719 as an add-on to Trikafta and a Phase 1 dual-combination trial of SION-451 with two complementary CFTR modulators, with topline data from both studies anticipated in the summer of 2026. It also established a $250.0 million at-the-market equity program but has not yet issued shares under it.
Sionna Therapeutics, Inc. reported first quarter 2026 results and a business update focused on its cystic fibrosis pipeline. The company completed enrollment in its PreciSION CF Phase 2a proof‑of‑concept trial of NBD1 stabilizer SION-719 as an add-on to standard of care, with topline data expected in summer 2026. An ongoing Phase 1 trial of NBD1 stabilizer SION-451 in dual combinations with SION-2222 and SION-109 is also on track for topline data in the summer.
Research and development expenses were $19.0 million and general and administrative expenses were $10.6 million for the quarter, leading to a net loss of $26.8 million, or $0.60 per share. Sionna ended March 31, 2026 with $289.9 million in cash, cash equivalents and marketable securities, which it expects to fund operations into 2028.
Sionna Therapeutics, Inc. director reporting person Peter A. Thompson reported indirect open-market sales of company common stock by an affiliated OrbiMed investment entity. Over three transactions on May 7, 8, and 11, 2026, the entity sold a total of 292,952 shares at prices between $44.58 and $46.22 per share under a pre-arranged Rule 10b5-1 trading plan. The shares are held of record by OrbiMed Private Investments VIII, LP, for which OrbiMed Capital GP VIII LLC and OrbiMed Advisors LLC may be deemed to share voting and investment power. Following these sales, the OrbiMed entity associated with the reporting person continues to hold 2,671,822 shares of Sionna Therapeutics common stock indirectly, with beneficial ownership disclaimed except to the extent of any pecuniary interest.
OrbiMed-affiliated funds reported open-market sales of Sionna Therapeutics, Inc. common stock. OrbiMed-related entity OrbiMed Private Investments VIII, LP sold 48,546 shares on May 7, 2026 at $44.61 per share, 59,767 shares on May 8, 2026 at $44.58 per share, and 184,639 shares on May 11, 2026 at $46.22 per share.
All sales were executed as open-market transactions pursuant to a Rule 10b5-1 trading plan. Following these transactions, the OrbiMed-affiliated holder reported owning 2,671,822 shares of Sionna Therapeutics common stock indirectly.